High Point Advisor Group LLC Autolus Therapeutics PLC Transaction History
High Point Advisor Group LLC
- $2.05 Billion
- Q3 2025
A detailed history of High Point Advisor Group LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, High Point Advisor Group LLC holds 88,300 shares of AUTL stock, worth $122,736. This represents 0.01% of its overall portfolio holdings.
Number of Shares
88,300
Previous 108,620
18.71%
Holding current value
$122,736
Previous $247,000
41.7%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding AUTL
# of Institutions
104Shares Held
150MCall Options Held
24.6KPut Options Held
41.9K-
Mak Capital One LLC New York, NY26MShares$36.2 Million6.54% of portfolio
-
Blackstone Inc New York, NY20.5MShares$28.5 Million0.15% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$23.1 Million97.83% of portfolio
-
Armistice Capital, LLC New York, NY15.6MShares$21.7 Million0.39% of portfolio
-
Tfg Asset Management Gp LTD Grand Cayman, E99.5MShares$13.2 Million3.44% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $126M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...